You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

indolent

Showing 1 - 25 of 626
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DALY on a Cohort of Patients With Indolent Systemic Mastocytosis

Recruiting
  • Mastocytosis, Indolent Systemic
    • Toulouse, Haute-Garonne, France
      Centre de Référence des Mastocytoses, Service de Dermatologie, H
    Jun 19, 2023

    Mantle Cell Lymphoma Trial (Zanubrutinib, Rituximab)

    Not yet recruiting
    • Mantle Cell Lymphoma
    • (no location specified)
    Nov 22, 2022

    Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of

    Active, not recruiting
    • Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
    • Copanlisib (BAY80-6946)
    • Multiple Locations, Taiwan
      Many Locations
    Jan 31, 2023

    Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

    Completed
    Has Results
    • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Sep 20, 2022

    Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

    Active, not recruiting
    • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
    • +22 more
    • External Beam Radiation Therapy
    • Orbital Radiation
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 9, 2022

    CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

    Terminated
    • CD20-positive Non-Hodgkin Lymphoma
    • Rituximab + MG4101
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Oct 24, 2022

    Lymphoma Trial in Houston (Ibritumomab Tiuxetan (Zevalin), Rituximab)

    Completed
    Has Results
    • Lymphoma
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Aug 30, 2022

    Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

    Recruiting
    • Follicular Lymphoma
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Indolent Lymphoma, Low-dose Radiotherapy Trial in Beijing (Low-dose radiotherapy)

    Recruiting
    • Indolent Lymphoma
    • Low-dose Radiotherapy
    • Low-dose radiotherapy
    • Beijing, Beijing, China
      National Cancer Center/National Clinical Research Center for Can
    Sep 13, 2022

    Severe COVID-19 Infection in CLL or B-NHL Who Received

    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
      • (no location specified)
      Apr 6, 2023

      Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Trial in Milano (intralesional rituximab, supplemental autologous

      Completed
      • Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
      • intralesional rituximab
      • supplemental autologous serum
      • Milano, Italy
        Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte T
      Aug 2, 2022

      Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

      Withdrawn
      • Recurrent Follicular Lymphoma
      • +8 more
      • (no location specified)
      Jun 2, 2022

      Waldenstrom Macroglobulinemia Trial in United States (Umbralisib)

      Completed
      • Waldenstrom Macroglobulinemia
      • Washington, District of Columbia
      • +3 more
      Oct 19, 2022

      Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

      Completed
      • Grade 3a Follicular Lymphoma
      • +9 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 31, 2023

      Lymphoma, B-Cell Trial in Guangzhou (Rituximab Biosimilar, Pegylated Interferon a-2b)

      Recruiting
      • Lymphoma, B-Cell
      • Rituximab Biosimilar
      • Pegylated Interferon α-2b
      • Guangzhou, Guangdong, China
        Department of Medical Oncology, Sun Yat-sen University Cancer Ce
      Apr 6, 2022

      Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)

      Recruiting
      • Inert Non Hodgkin's Lymphoma
      • Beijing, China
        Biotherapeutic Department, Chinese PLA General Hospital
      Feb 19, 2022

      Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia Trial in Australia,

      Recruiting
      • Follicular Lymphoma
      • +7 more
      • Louisville, Kentucky
      • +4 more
      Mar 11, 2022

      Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

      Active, not recruiting
      • Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
      • Nagoya, Aichi, Japan
      • +5 more
      Dec 10, 2021

      Indolent B-Cell Non-Hodgkin Lymphoma Trial in Worldwide (BI1206)

      Recruiting
      • Indolent B-Cell Non-Hodgkin Lymphoma
      • BI1206
      • Atlanta, Georgia
      • +8 more
      Mar 1, 2022

      Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spokane, Salamanca (Zilovertamab vedotin,

      Recruiting
      • Chronic Lymphocytic Leukemia
      • +3 more
      • Spokane, Washington
      • +1 more
      Aug 12, 2022

      Indolent Systemic Mastocytosis Trial in France, Germany, United States (Masitinib, Placebo, Best Supportive Care)

      Recruiting
      • Indolent Systemic Mastocytosis
      • Rochester, Minnesota
      • +6 more
      Nov 29, 2021

      Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia Trial in Bergamo (Blinatumomab Expanded T-cells (BET))

      Active, not recruiting
      • Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
      • Blinatumomab Expanded T-cells (BET)
      • Bergamo, Italy
        ASST - Papa Giovanni XXIII
      Dec 22, 2021

      Non Hodgkin's Lymphoma Trial in Sacramento, Santa Rosa (Rituximab, Lenalidomide)

      Active, not recruiting
      • Non Hodgkin's Lymphoma
      • Sacramento, California
      • +1 more
      Nov 15, 2021

      Mastocytosis Trial in Toulouse (Hydroxychloroquine)

      Not yet recruiting
      • Mastocytosis
      • Toulouse, France
        Larrey Hospital - Toulouse University Hospital
      Oct 6, 2021

      Follicular Lymphoma, Marginal Zone Lymphoma Trial in Italy, Spain, United States (EO2463, lenalidomide, rituximab)

      Recruiting
      • Follicular Lymphoma
      • Marginal Zone Lymphoma
      • EO2463
      • +2 more
      • Boston, Massachusetts
      • +9 more
      Jul 26, 2022